

SEQUENCE LISTING

<110> PROUDFOOT, AMANDA
SHAW, JEFFREY
JOHNSON, ZOE

<120> THERAPEUTIC USES OF CHEMOKINE VARIANTS

<130> ARS-124

<140> US 10/573, 625
<141> 2006-03-28

<150> EP 03078308
<151> 2003-10-16

<160> 5

<170> PatentIn version 3.0

<210> 1
<211> 76
<212> PRT
<213> Homo sapiens

<220>
<223> Human CCL2

<400> 1

Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr
1 5 10 15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
20 25 30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
35 40 45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met
50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
65 70 75

<210> 2
<211> 76
<212> PRT
<213> synthetic construct

<220>
<223> Human CCL2-P8A

<400> 2

Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr
 1 5 10 15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
 20 25 30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
 35 40 45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met
 50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
 65 70 75

<210> 3

<211> 76

<212> PRT

<213> synthetic construct

<220>

<223> Human CCL2*

<400> 3

Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr
 1 5 10 15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
 20 25 30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
 35 40 45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile
 50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
 65 70 75

<210> 4

<211> 76

<212> PRT

<213> synthetic construct

<220>

<223> Human CCL2*-P8A

<400> 4

Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr

1	5	10	15
Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr			
20	25	30	

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala			
35	40	45	

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile			
50	55	60	

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr			
65	70	75	

<210> 5

<211> 331

<212> PRT

<213> synthetic construct

<220>

<223> Human CCL2-P8A_IgG1 fusion protein

<400> 5

Met Lys Val Ser Ala Ala Leu Leu Cys Leu Leu Leu Ile Ala Ala Thr			
1	5	10	15

Phe Ile Pro Gln Gly Leu Ala Gln Pro Asp Ala Ile Asn Ala Ala Val			
20	25	30	

Thr Cys Cys Tyr Asn Phe Thr Asn Arg Lys Ile Ser Val Gln Arg Leu			
35	40	45	

Ala Ser Tyr Arg Arg Ile Thr Ser Ser Lys Cys Pro Lys Glu Ala Val			
50	55	60	

Ile Phe Lys Thr Ile Val Ala Lys Glu Ile Cys Ala Asp Pro Lys Gln			
65	70	75	80

Lys Trp Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr Gln Thr			
85	90	95	

Pro Lys Thr Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro			
100	105	110	

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro			
115	120	125	

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr			
130	135	140	

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn			
145	150	155	160

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
165 170 175

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
180 185 190

Leu His Asn Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
195 200 205

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
210 215 220

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
225 230 235 240

Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
245 250 255

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Gln Gly Gln Pro Glu
260 265 270

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
275 280 285

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
290 295 300

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
305 310 315 320

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330